anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-04 and is reviewed periodically as new material appears.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
== Drinking water hazards == Untreated water may contain potentially pathogenic agents, including protozoa, bacteria, viruses, and some larvae of higher-order parasites such as liver flukes and roundworms. Chemical pollutants such as pesticides, heavy metals and synthetic organics may be present. Other components may affect taste, odour and general aesthetic qualities, including turbidity from soil or clay, colour from humic acid or microscopic algae, odours from certain type of bacteria, particularly Actinomycetes which produce geosmin, and saltiness from brackish or sea water. Common metallic contaminants such as copper and lead can be treated by increasing the pH using soda ash or lime, which precipitates such metals. Careful decanting of the clear water after settlement or the use of filtration provides acceptably low levels of metals. Water contaminated by aluminium or zinc cannot be treated in this way using a strong alkali as higher pHs re-dissolve the metal salts. Salt is difficult to remove except by reverse osmosis or distillation. Most portable treatment processes focus on mitigating human pathogens for safety and removing particulates matter, tastes and odours. Significant pathogens commonly present in the developed world include Giardia, Cryptosporidium, Shigella, hepatitis A virus, Escherichia coli, and enterovirus. In less developed countries there may be risks from cholera and dysentery organisms and a range of tropical enteroparasites.
=== Liver fatty acid storage === In a high-fat diet-induced obesity model of fatty liver disease (i.e., excessive buildup of fat in the liver), mice fed a diet that increased intestinal levels of SC-FAs showed reductions in their livers' synthesis of lipids, triglyceride levels, and weights. These reductions did not occur in Ffar3 gene knockout mice but did occur in Ffar2 gene knocked-out mice. These results indicate that the SC-FA-induced activation of FFAR3 suppresses the liver's accumulation of fatty acids that underlies the development of fatty liver disease in this mouse model. Other studies have found that Ffar3 gene knockout mice showed less weight gain than wild-type mice under standard laboratory conditions, but this difference was lost in mice reared under germ-free conditions (i.e., which causes the mice to have lower intestinal and tissue levels of SC-FAs). These findings indicated that the activation of FFAR3 but not FFAR2 by SC-FAs protects against developing fatty liver disease in mice.
C4 plants use a different metabolic pathway to capture carbon dioxide but also have differences in leaf anatomy and cell biology compared to most other plants. Trunk, a single woody stem came about in unrelated plants: paleozoic tree forms of club mosses, horsetails, and seed plants. The marine animals sea lily crinoid, looks like a terrestrial palm tree. Palm trees form are in unrelated plants: cycads (from the Jurassic period) and older tree ferns. Flower petals came about independently in a number of different plant lineages. Bilateral flowers, with distinct up-down orientation, came about independently in a number of different plants like: violets, orchids and peas. United petals, petals that unite into a single bell shape came about independently in blueberries, Ericaceae and other plants. Hummingbird flowers are scentless tubular flowers that have independently came about in at least four plant families. They attract nectar-feeding birds like: hummingbirds, honey eaters, sunbirds. Remote Hawaii also has hummingbird flowers. Carrion flower type flowers that smell like rotting meat have independently came about in: pawpaw (family Annonaceae), the giant Indonesian parasitic flower Rafflesia, and African milkweed (Stapelia gigantea). Fruit that develops underground, after the upper part is pollinated the flower stalk elongates, arches downward and pushes into the ground, this has independently came about in: peanut, legume, Florida's endangered burrowing four o'clock and Africa's Cucumis humifructus.
=== Acute care and monitoring === Acute care and monitoring (ACM) is based out of Lafayette, Colorado and produces non-invasive sensors and monitoring products, used for patient monitoring in the hospital and home settings. It has absorbed the portfolios of acquired companies, including Covidien, Nellcor, Somanetics, Aspect Medical Systems, Oridion Medical and Zephyr Technology. This business unit produces pulse oximetry, capnography, and bispectral index sensors, patient monitors, remote patient monitoring software, and electronic medical record connectivity software.
Directed by Ben Stiller, the film was a satirical black comedy, in which Carrey played a lonely, menacing cable television installer who infiltrates the life of one of his customers (played by Matthew Broderick). The role was a departure from the "hapless, hyper, overconfident" characters he had been known for. However, it did not fare well with most critics, many reacting to Carrey's change of tone from previous films. Carrey also starred in the music video of the film's closing song, "Leave Me Alone" by Jerry Cantrell. Despite the reviews, The Cable Guy grossed $102 million worldwide. He soon bounced back with the critically acclaimed comedy Liar Liar (1997), playing Fletcher Reede, an unethical lawyer rendered unable to lie by his young son's birthday wish. Carrey was praised for his performance, earning a second Golden Globe Award nomination for Best Actor. Janet Maslin of The New York Times said: "Well into his tumultuous career, Mr. Carrey finally turns up in a straightforward comic vehicle, and the results are much wilder and funnier than this mundane material should have allowed." The following year he decided to take a pay cut to play the seriocomic role of Truman Burbank in the satirical comedy-drama film The Truman Show (1998). The film was highly praised and brought Carrey further international acclaim, leading many to believe he would be nominated for an Academy Award. He won the Golden Globe Award for Best Actor in a Motion Picture Drama but did not receive an Academy Award nomination.
Sources: en.wikipedia.org
== Research and development == In November 2013, Discovery Laboratories began its phase II clinical program of aerosolized KL4 since U.S. Food and Drug Administration (FDA) had cleared the investigational new drug (IND) application. The phase II consists of two steps to evaluate the safety and tolerability of the drug and determine the optimal dose for premature infants with respiratory distress syndrome (RDS) In October 2013, Discovery Laboratories received the agreement of updating Surfaxin (lucinactant) Intratracheal Suspension from the U.S. Food and Drug Administration (FDA) to prevent respiratory distress syndrome (RDS) in premature infants. In September 2012, Discovery Laboratories started the four research projects to explore the KL4 surfactant technology for acute lung injury (ALI). These projects are funded through government-sponsored, biodefense-related initiatives under the Project Bioshield Act of 2004 and the Pandemic and All-Hazards Preparedness Act of 2006.
The main secondary aspect of the Discipline is that the avout are allowed to own only their "bolt, chord, and sphere". These objects are made with "newmatter" (matter made with a modified atomic structure to be more versatile), and can be made to alter their shape, texture and other physical properties without the use of tools or other outside technologies. The bolt is a length of newmatter fabric and is used as clothing; the chord is a newmatter rope used to secure the bolt; and the sphere is a newmatter balloon of adjustable size, shape and hardness, and serves as a multipurpose tool. There are several restrictions governing, for example, the use of "sequencing" (genetic engineering), "syntactic devices" (computers), or other "praxis" (technology). Due to the restrictions, avout can only work on an entirely theoretical basis de jure.
=== Administrative history === The town was historically a chapelry in the ancient parish of Great Burstead. The Billericay Poor Law Union, created in 1835, gradually took on local government powers, becoming a rural sanitary district in 1872; this in turn became the Billericay Rural District in 1894, when a Great Burstead Parish Council was also created covering the parish. The rural district covered a large area stretching as far as Brentwood and Pitsea. In 1934, most of the rural district was reconstituted as Billericay Urban District and the parish councils within the area were abolished. Three years later, all the urban parishes within the district were united into a civil parish of Billericay. The urban district, but not the parish, was renamed Basildon in 1955, although the council continued to be based at the Town Hall and adjoining offices in Billericay until the early 1960s, when it moved into new premises in Basildon itself. In 1974, through enactment of the Local Government Act 1972, the Basildon Urban District was reconstituted as the modern Basildon district and the civil parish of Billericay was abolished, becoming an unparished area. A new civil parish of Billericay was established in 1996, this time just covering the town itself rather than the whole Basildon district.
GSK-3 functions by phosphorylating a serine or threonine residue on its target substrate. A positively charged pocket adjacent to the active site binds a "priming" phosphate group attached to a serine or threonine four residues C-terminal of the target phosphorylation site. The active site, at residues 181, 200, 97, and 85, binds the terminal phosphate of ATP and transfers it to the target location on the substrate (see figure 1).
== Synthetic/native nanodisc == Another way to mimic the native lipid membrane are synthetic polymers. Styrene-maleic acid co-polymers (SMAs) called SMALPs or Lipodisq and Diisobutylene-maleic acid (DIBMA) are such synthetic polymers (DIBMALPs). They can solubilize membrane proteins directly from cells or raw extract. They also have been used to study the lipid composition of several organisms. It was discovered that all synthetic polymers which contained a styrene and maleic acid group can solubilize proteins. These SMA nanoparticles have also been tested as possible drug delivery vehicle and for the study of folding, post-translational modifications and lipid interactions of membrane proteins by native mass spectrometry. They are now routinely used to solve membrane protein structures for cryo-EM, such as the aerolysin pore-forming toxins (2.1Å resolution), where some lipid density was modelled and key interactions relevant for the understanding of pore formation mechanism, its correct positioning and anchoring in the membrane were elucidated.
Sources: en.wikipedia.org
== Taxonomy == FishBase recognizes four species in the genus. In addition to these, evidence suggests that a fifth species, A. arapaima, should be recognized (this being the widespread, well-known species, otherwise included in A. gigas).
Bavington, Dean L. Y. Managed Annihilation: An Unnatural History of the Newfoundland Cod Collapse (University of British Columbia Press; 2010) 224 pages. Links the collapse of Newfoundland and Labrador cod fishing to state management of the resource. Cobb, John N. (1916). Pacific Cod Fisheries. Bureau of Fisheries Document. Vol. 830. Washington, DC: Government Printing Office. OCLC 14263968. Greenberg, Paul (2010). Four Fish: The Future of the Last Wild Food. New York: Penguin Press. ISBN 978-1-59420-256-8. OCLC 813929026. Mark Kurlansky (1997). Cod: A Biography of the Fish That Changed the World. Shields, Edward (2001). Salt of the Sea: The Pacific Coast Cod Fishery and the Last Days of Sail. Lopez Island, Wash.: Heritage House. ISBN 978-1-894384-35-3.
== Production == Brilliant blue FCF is a synthetic dye produced by the condensation of 2-formylbenzenesulfonic acid and the appropriate aniline followed by oxidation. It can be combined with tartrazine (E102) to produce various shades of green. It is usually a disodium salt. The diammonium salt has CAS number 2650-18-2. Calcium and potassium salts are also permitted. It can also appear as an aluminium lake. The chemical formula is C37H34N2Na2O9S3. Related dyes are C.I. acid green 3 (CAS#4680-78-8) and acid green 9 (CAS#4857-81-2). In these dyes, the 2-sulfonic acid group is replaced by H and Cl, respectively. Many attempts have been made to find similarly colored natural dyes that are as stable as brilliant blue FCF. Blue pigments must possess many chemical traits, including pi-bond conjugation, aromatic rings, heteroatoms and heteroatom groups, and ionic charges in order to absorb low energy red light. Most natural blue dyes are either unstable, blue only in alkaline conditions, or toxic; good candidates for further research into use as natural dyes include anthocyanin, trichotomine, and phycocyanin derivatives.
While the initial consolidation of Air Force laboratories reduced overhead and budgetary pressure, another push towards a unified laboratory structure came in the form of the National Defense Authorization Act for Fiscal Year 1996, Section 277. This section instructed the Department of Defense to produce a five-year plan for consolidation and restructuring of all defense laboratories. The currently existing laboratory structure was created in October 1997 through the consolidation of Phillips Laboratory headquartered in Albuquerque, New Mexico, Wright Laboratory in Dayton, Ohio, Rome Laboratory (formerly Rome Air Development Center) in Rome, New York, and Armstrong Laboratory in San Antonio, Texas and the Air Force Office of Scientific Research (AFOSR). The single laboratory concept was developed and championed by Maj Gen Richard Paul, who was Director of Science & Technology for AFMC and Gen Henry Viccellio Jr, and then became the first Commander of AFRL.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.